Anemia in heart failure: Pathophysiologic insights and treatment options

Future Cardiology

Volumn 5, Issue 1, 2009, Pages 71-81

  Terrovitis, John V ^a   Anastasiou Nana, Maria ^a   Kaldara, Elissavet ^a   Drakos, Stavros G ^a   Nanas, Serafeim N ^a   Nanas, John N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anemia; Darbepoetin; Erythropoietin; Erythropoietin stimulating agents; Heart failure; Iron; Renal dysfunction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CARVEDILOL; DEXTRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; FOLIC ACID; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; IRON; METOPROLOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ANEMIA; ATHEROSCLEROSIS; BACTEREMIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEMODILUTION; HUMAN; IRON DEFICIENCY; KIDNEY DYSFUNCTION; MONOTHERAPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANEMIA; ANEMIA, IRON-DEFICIENCY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; CYTOKINES; ERYTHROPOIETIN; HEART FAILURE; HEMODILUTION; HUMANS; KIDNEY DISEASES; PREVALENCE; PROGNOSIS; RECEPTORS, ANGIOTENSIN;

EID: 66949120004     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.5.1.71     Document Type: Review

References (88)

1. Hunt SA, Abraham WT, Chin MH et al.: ACC/AHA 2005 guideline update for the diagnosis arid management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Asscciation Task Force on practice guidelines (writing committee to update the 2001 guidelines fdr the evaluation and management of heart failure): developed in collaboration with the American College of Cbest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112, E154-E235 (2005).
2. Anand I, McMurray JJ, Whitmore J et al.: Anemia and its relationship to clinical outcome in heart failure. Circulation 110, 149-154 (2004).
3. Anand IS, Kuskowski MA, Rector TS et al.: Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112, 1121-1127 (2005).
4. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL: Anemia and heart failure: a community study. Am. J. Med. 121, 726-732 (2008).
5. Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107, 223-225 (2003).
6. Groenveld HF, Januzzi JL, Damman K et al.: Anemia and mortality in heart failure patients a systematic review and meta-analysis. J. Am. Coll. Cardiol. 52, 818-827 (2008).
7. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortallity in patients with advanced heart failure. J. Am. Coll. Cardiol. 39, 1180-1786 (2002).
8. Maggioni AP, Opasich C, Anand I et al.: Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J. Card. Fail. 11, 91-98 (2005).
9. Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in severe heart failure: the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). J. Am. Coll. Cardiol. 41, 1933-1939 (2003).
10. Wexler D, Silverberg D, Sheps D et al.: Prevalence of anemia in patients admitted th hospital with a primary diagnosis of congestive heart failure. Int. J. Cardiol. 96, 79-87 (2004).
11. Young JB, Abraham WT, Albert NM et al.: Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am. J. Cardiol. 101, 223-230 (2008).
12. Al-Ahmad A, Rand WM, Manjunath G et al.: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 38, 955-962 (2001).
13. de Silva R, Rigby AS, Witte KK et al.: Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am. J. Cardiol. 98, 391-398 (2006).
14. Ezekowitz JA, McAlister FA, Armstrong PW: The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. Can. J. Cardiol. 21, 165-171 (2005).
15. Silverberg DS, Wexler D, Blum M et al.: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 35, 1737-1744 (2000).
16. Felker GM, Gattis WA, Leimberger JD et al.: Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am. J. Cardiol. 92, 625-628 (2003).
17. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J. Am. Soc. Nephrol. 13, 1928-1936 (2002).
18. Cleland JG, Swedberg K, Follath F et al.: The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur. Heart J. 24, 442-463 (2003).
19. Brucks S, Little WC, Chao T et al.: Relation of anemia to diastolic heart failure and the effect on outcome. Am. J. Cardiol. 93, 1055-1057 (2004).
20. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL: Are hematinic deficiencies the cause of anemia in chronic heart failure? Am. Heart J. 147, 924-930 (2004).
21. Grigorian Shamagian L, Varela Roman A, Garcia-Acuna JM, Mazon Ramos P, Virgos Lamela A, Gonzalez-Juanatey JR: Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function. Heart 92, 780-784 (2006).
22. Anand IS: Anemia and chronic heart failure implications and treatment options. J. Am. Coll. Cardiol. 52, 501-511 (2008).
23. Anand IS: Heart ailure and anemia: mechanisms and pathophysiology. Heart Fail. Rev. 13, 379-386 (2008).
24. Okonko DO, Anker SD: Anemia in chronic heart failure: pathogenetic mechanisms. J. Card. Fail. 10, S5-S9 (2004).
25. Nemeth E, Rivera S, Gabayan V et al.: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest 113, 1271-1276 (2004).
26. Nanas JN, Matsouka C, Karageorgopoulus D et al.: Etiology of anemia in patients with advanced heart failure. J. Am. Coll. Cardiol. 48, 2485-2489 (2006).
27. Weiss G, Goodnough LT: Anemia of chronic disease. N. Engl. J. Med. 352, 1011-1023 (2005).
28. Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A: The association between congestive heart failure and chronic renal disease. Curr. Opin. Nephrol. Hypertens. 13, 163-170 (2004).
29. Jie KE, Verhaar MC, Cramer MJ et al.: Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am. J. Physiol. Renal Physiol. 291, F932-F944 (2006).
30. George J, Patal S, Wexler D et al.: Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch. Intern. Med. 165, 1304-1309 (2005).
31. Volpe M, Tritto C, Testa U et al.: Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am. J. Cardiol. 74, 468-473 (1994).
32. Iaina A, Silverberg DS, Wexler D: Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome. Nat. Clin. Pract. Cardiovasc. Med. 2, 95-100 (2005).
33. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D: Anemia, chronic renal disease and congestive heart failure - the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int. Urol. Nephrol. 38, 295-310 (2006).
34. Anand IS: Pathogenesis of anemia in cardiorenal disease. Rev. Cardiovasc. Med. 6(Suppl. 3), S13-S21 (2005).
35. Opasich C, Cazzola M, Scelsi L et al.: Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur. Heart J. 26, 2232-2237 (2005).
36. Goicoechea M, Martin J, de SP et al.: Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 54, 1337-1343 (1998).
37. van der Putten K, Braam B, Jie KE, Gaillard CA: Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nat. Clin. Pract. Nephrol. 4, 47-57 (2008).
38. Iversen PO, Woldbaek PR, Tonnessen T, Christensen G: Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282, R166-R172 (2002).
39. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236-241 (1990).
40. Jelkmann W: Proinflammatory cytokines lowering erythropoietin production. J. Interferon Cytokine Res. 18, 555-559 (1998).
41. van der Meer P, Lok DJ, Januzzi JL et al.: Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur. Heart. J. 29, 1510-1515 (2008)
42. Androne AS, Katz SD, Lund L et al.: Hemodilution is common in patients with advanced heart failure. Circulation 107, 226-229 (2003).
43. Westenbrink BD, Visser FW, Voors AA et al.: Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur. Heart J. 28, 166-171 (2007).
44. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol. Dial. Transplant. 13, 1206-1210 (1998).
45. Julian BA, Brantley RR Jr, Barker CV et al.: Losartan, an angiotensin II type 1 receptor antagonist lowers hematocrit in posttransplant erythrocytosis. J. Am. Soc. Nephrol. 9, 1104-1108 (1998).
46. Chatterjee B, Nydegger UE, Mohacsi P: Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur. J. Heart Fail. 2, 393-398 (2000).
47. van der Meer P, Lipsic E, Westenbrink BD et al.: Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112, 1745-1747 (2005).
48. Marathias KP, Agroyannis B, Mavromoustakos T, Matsoukas J, Vlahakos DV: Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr. Top. Med. Chem. 4, 483-486 (2004).
49. Terrovitis JV, Anastasiou-Nana MI, Alexopoulos GP et al.: Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril. J. Heart Lung Transplant. 25, 333-338 (2006).
50. Go AS, Yang J, Ackerson LM et al.: Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) study. Circulation 113, 2713-2723 (2006).
51. Komajda M, Anker SD, Charlesworth A et al.: The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur. Heart J. 27, 1440-1446 (2006),
52. Levy WC: Anemia in heart failure: marker or mediator of adverse prognosis? J. Am. Coll. Cardiol. 51, 577-578 (2008).
53. Kosiborod M, Curtis JP, Wang Y et al.: Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch. Intern. Med. 165, 2237-2244 (2005).
54. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC: Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br. Heart J. 70, 357-362 (1993).
55. Olivetti G, Quaini F, Lagrasta C et al.: Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am. J. Pathol. 141, 227-239 (1992).
56. Kalra PR, Bolger AP, Francis DP et al.: Effect of anemia on exercise tolerance in chronic heart failure in men. Am. J. Cardiol. 91, 888-891 (2003).
57. Anand IS, Chandrashekhar Y, Wander GS, Chawla LS: Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J. Am. Coll. Cardiol. 25, 1402-1407 (1995).
58. Maschio G: Erythropoietin and systemic hypertension. Nephrol. Dial. Transplant 10(Suppl. 2), 74-79 (1995).
59. Levin A, Djurdjev O, Thompson C et al.: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am. J. Kidney Dis. 46, 799-811 (2005).
60. Drueke TB, Locatelli F, Clyne N et al.: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071-2084 (2006).
61. Silverberg DS, Wexler D, Blum M et al.: Effects of treatment with epoetin β on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press. Res. 28, 41-47 (2005).
62. Silverberg DS, Wexler D, Sheps D et al.: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37, 1775-1780 (2001).
63. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107, 294-299 (2003).
64. Palazzuoli A, Silverberg D, Iovine F et al.: Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am. Heart J. 152, 1096 E9-E15 (2006).
65. Palazzuoli A, Silverberg DS, Iovine F et al.: Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am. Heart J. 154, 645 E9-E15 (2007).
66. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH: Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J. Am. Coll. Cardiol. 48, 2161-2167 (2006).
67. Lipsic E, Westenbrink BD, van der MP et al.: Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur. J. Heart Fail. 10, 22-29 (2008).
68. Hirata A, Minamino T, Asanuma H et al.: Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol. 48, 176-184 (2006).
69. Hirata A, Minamino T, Asanuma H et al.: Erythropoietin just before reperfusion reduces - both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc. Drugs Ther. 19, 33-40 (2005).
70. Westenbrink BD, Lipsic E, van der Meer P et al.: Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur. Heart J. 28, 2018-2027 (2007).
71. Ponikowski P, Anker SD, Szachniewicz J et al.: Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 49, 753-762 (2007).
72. van Veldhuisen DJ, Dickstein K, Cohen-Solal A et al.: Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur. Heart J. 28, 2208-2216 (2007).
73. Besarab A, Bolton WK, Browne JK et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584-590 (1998).
74. Bohlius J, Wilson J, Seidenfeld J et al.: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 98, 708-714 (2006).
75. Bennett CL, Silver SM, Djulbegovic B et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299, 914-924 (2008).
76. Ghali JK, Anand IS, Abraham WT et al.: Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117, 526-535 (2008).
77. van Veldhuisen DJ, McMurray JJ: Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powereci randomised outcome trial. Eur. J. Heart Fail. 9, 110-112 (2007).
78. Bolger AP, Bartlett FR. Penston HS et al.: Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J. Am. Coll. Cardiol. 48, 1225-1227 (2006).
79. Okonko DO, Grzeslo A, Witkowski T et al.: Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol. 51, 103-112 (2008).
80. Slotki I: Intravenous iron supplementation in the anaemia of renal and cardiac failure - a double-edged sword? Nephrol. Dial. Transplant 20 (Suppl. 7), vii16-23 (2005).
81. Zager RA, Johnson AC, Hanson SY: Parenteral iron therapy exacerbates experimental sepsis. Kidney Int. 65, 2108-2112 (2004).
82. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 27, 343-350 (2007).
83. Auerbach M, Ballard H, Glaspy J: Clinical update: intravenous iron for anaemia. Lancet 369, 1502-1504 (2007).
84. Drueke T, Witko-Sarsat V, Massy Z et al.: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106, 2212-2217 (2002).
85. Van Wyck D, Anderson J, Johnson K: Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol. Dial. Transplant 19, 561-565 (2004).
86. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC et al.: Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J. Card. Fail. 13, 14-17 (2007).
87. Punnonen K, Irjala K, Rajamaki A: Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 89, 1052-1057 (1997).
88. Macdougall IC: Recent advances in erythropoietic agents in renal anemia. Semin. Nephrol. 26, 313-318 (2006).